Aripiprazole Tablet
Product Images NDC 70518-2643

13 FDA label images from Remedyrepack Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 70518-2643). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Description Image (Structure)

Description Image (Structure)
Chemical structure of aripiprazole, showing its molecular framework with distinct chlorine atoms and multiple ring systems connected by various linkages.*
FDA Label Image

Image 1 (Figure 1)

Image 1 (Figure 1)
A pharmacokinetic chart titled 'The Effect of Other Drugs on Aripiprazole Pharmacokinetics,' showing the fold change and 90% confidence intervals of aripiprazole exposure (AUC and Cmax) when co-administered with various drugs including CYP3A4 and CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs such as valproate, lithium, and lorazepam. The x-axis represents change relative to reference (no interacting drug) ranging from 0.5 to 3.0.*
FDA Label Image

Image 2 (Figure 2)

Image 2 (Figure 2)
A horizontal bar plot titled 'The Effect of Other Drugs on Dehydro-Aripiprazole Pharmacokinetics' showing fold change and 90% confidence intervals for area under the curve (AUC) and maximum concentration (Cmax) relative to reference without interacting drugs. It compares effects of drugs such as ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam on dehydro-aripiprazole pharmacokinetics.*
FDA Label Image

Image 3 (Figure 3)

Image 3 (Figure 3)
A pharmacokinetic chart titled 'Effect of Aripiprazole on Other Drugs' showing fold change and 90% confidence intervals for various drugs relative to a reference without interacting drug. The graph lists drugs such as dextromethorphan, warfarin, omeprazole, lithium, lorazepam, venlafaxine, and escitalopram, with separate measures for PK parameters like AUC, Cmax, and INR, plotted against a horizontal axis labeled 'Change Relative to Reference (without interacting drug)' with values from 0.5 to 3.0.*
FDA Label Image

Image 4 (Figure 4)

Image 4 (Figure 4)
A scientific chart titled 'Effect of Intrinsic Factors on Aripiprazole Pharmacokinetics' illustrating the impact of special populations on pharmacokinetic parameters AUC and Cmax. The graph shows fold change and 90% confidence intervals of Aripiprazole exposure relative to reference across categories such as CYP2D6 metabolism status, gender, age groups, hepatic impairment levels, and severe renal impairment.*
FDA Label Image

Image 5 (Figure 5)

Image 5 (Figure 5)
A pharmacokinetic chart titled 'Effect of Intrinsic Factors on Dehydro-aripiprazole Pharmacokinetics' showing fold change and 90% confidence intervals for various conditions compared to reference. Factors include CYP2D6 metabolism status, gender, age, hepatic impairment (mild, moderate, severe), and severe renal impairment, with fold changes plotted for AUC and Cmax values relative to reference.*
FDA Label Image

Fig-6 (Figure 6)

Fig-6 (Figure 6)
Kaplan-Meier estimation chart showing the cumulative proportion of patients with relapse over time (days from randomization) in a schizophrenia study. The graph compares two groups: one treated with aripiprazole and one with placebo. The y-axis represents the proportion with relapse, and the x-axis shows days from randomization along with the number of subjects at risk at various time points.*
FDA Label Image

7 (Figure 7)

7 (Figure 7)
Kaplan-Meier estimation graph showing the cumulative proportion of patients with relapse over days from randomization in a bipolar disorder study. The graph compares relapse rates between aripiprazole and placebo groups, with the number of subjects at risk displayed beneath the x-axis over time.*
FDA Label Image

8 (Figure 8)

8 (Figure 8)
Kaplan-Meier estimation chart showing the cumulative proportion of patients with relapse to any mood event over 364 days from randomization in Bipolar Study 8. The chart compares relapse proportions between aripiprazole and placebo groups, with the x-axis representing days and the y-axis representing proportion with relapse. A table below the x-axis shows the number of subjects at risk over time for both groups.*
FDA Label Image

9 (Figure 9)

9 (Figure 9)
A line graph depicting the least squares mean change from baseline in YGTSS total tic score over 8 weeks of treatment. The graph compares two doses of aripiprazole (low and high) with placebo, showing the change in tic score on the vertical axis and weeks of treatment on the horizontal axis.*
FDA Label Image

Mm1 (Aripiprazole 15mg 70518 2643 00)

Mm1 (Aripiprazole 15mg 70518 2643 00)
Aripiprazole Tablet 15 mg in a package containing 30 tablets. The label shows the product NDC 70518-2643-00, repackaged by RemedyRepack Inc., Indiana, PA. It includes storage instructions and manufacturer information for Torrent Pharma Inc., Basking Ridge, NJ.*
FDA Label Image

Mm2 (Aripiprazole 15mg 70518 2643 01)

Mm2 (Aripiprazole 15mg 70518 2643 01)
Aripiprazole 15 mg oral tablets, packaged in a box of 50 tablets. The label indicates the product is repackaged by RemedyRepack Inc. and provides storage instructions. The label includes the NDC number 70518-2643-01 and notes the tablet is round and white.*
FDA Label Image

Mm3 (Aripiprazole 15mg 70518 2643 02)

Mm3 (Aripiprazole 15mg 70518 2643 02)
Aripiprazole Tablet 15 mg oral tablet single unit package with a white round tablet shown. Label indicates NDC 70518-2643-02, repackaged by RemedyRepack Inc., Indiana, PA. Manufacturer is Torrent Pharma Inc., Basking Ridge, NJ. Storage instructions and dosage note included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.